glp 1 medication medicaid Medicare, decline to cover popular weight loss drugs for obesity GLP-1s prescriptions for weight loss

CagriSema (semaglutide + cagrilintide), filed by Novo Nordisk in December 2025, achieved 22.7% weight loss in trials and could receive FDA approval in 2026

Baker & Hostetler LLP has a great introductory and analysis piece on the green list if you need the background

However, variability in individual responses underscores the complexity of their effects and highlights the need to identify patient subgroups most likely to benefit from this therapy

[DOI] [PubMed] [Google Scholar] 47.Heerspink HJ, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al

Consider scheduling your injection on Friday so initial side effects occur over the weekend, prioritise rest during off-hours, and implement the energy management strategies discussed in this article